News & Events about Ligand Pharmaceuticals Incorporated.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum...
Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS)One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational lasofoxifene versus fulvestrantSecond abstract addressed patients who participated in a single-arm ...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at todays Investor and Analyst Day event its executive management provided an overview of Ligands corporate structure and business following the successful spin-off of its OmniAb antibody discovery business, reviewed Ligands recent...
Study evaluated safety, tolerability and pharmacokinetics of oral lasofoxifene in healthy Japanese and Caucasian womenCOLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ...
Globe Newswire
2 months ago
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it had four abstracts accepted ...